Characteristics | No statin (n = 1156) | Non-titrators (n = 4916) | Titrators (n = 1565) | Full cohort (n = 11,499) |
---|---|---|---|---|
Total Patients, n (%) | 1155 (100) | 4916 (100) | 1565 (100) | 11,499 (100) |
Age (year), mean (SD) | 65.3 (11.0) | 69.0 (10.3) | 64.8 (10.0) | 67.8 (11.3) |
Sex, males, n (%) | 461 (39.9) | 2008 (40.8) | 712 (45.5) | 4967 (43.2) |
Race, n (%) | ||||
Chinese | 1042 (90.2) | 4185 (85.1) | 1279 (81.7) | 9606 (83.5) |
Malay | 22 (1.9) | 282 (5.7) | 109 (7.0) | 726 (6.3) |
Indian | 55 (4.8) | 236 (4.8) | 105 (6.7) | 655 (5.7) |
Others | 36 (3.1) | 213 (4.3) | 72 (4.6) | 512 (4.5) |
Diagnosis, n (%) | ||||
Dyslipidaemia | 1155 (100.0) | 4916 (100.0) | 1565 (100.0) | 11,499 (100.0) |
Diabetes | 159 (13.8) | 1915 (39.0) | 594 (38.0) | 4153 (36.1) |
Hypertension | 793 (68.7) | 4166 (84.7) | 1120 (71.6) | 9101 (79.1) |
Years with Dyslipidaemia at base visit, n (%) | ||||
0 | 196 (17.0) | 226 (4.6) | 177 (11.3) | 1074 (9.3) |
1 | 76 (6.6) | 298 (6.1) | 125 (8.0) | 797 (6.9) |
2 | 81 (7.0) | 600 (12.2) | 184 (11.8) | 1350 (11.7) |
3 | 103 (8.9) | 316 (6.4) | 121 (7.7) | 825 (7.2) |
4 | 183 (15.8) | 417 (8.5) | 159 (10.2) | 1133 (9.9) |
> =5 | 516 (44.7) | 3059 (62.2) | 799 (51.0) | 6320 (55.0) |
Statin intensity at base visit, n (%) | ||||
No | 1155 (100.0) | 0.0 (0.0) | 333 (21.3) | 2327 (20.2) |
Low | 0.0 (0.0) | 3998 (81.3) | 850 (54.3) | 7076 (61.5) |
Intermediate | 0.0 (0.0) | 812 (16.5) | 349 (22.3) | 1867 (16.2) |
High | 0.0 (0.0) | 106 (2.2) | 33 (2.1) | 229 (2.0) |
Patients in each risk group, n (%) | ||||
Low | 515 (44.6) | 1111 (22.6) | 453 (28.9) | 2970 (25.8) |
Intermediate | 196 (17.0) | 504 (10.3) | 150 (9.6) | 1162 (10.1) |
High | 331 (28.7) | 1827 (37.2) | 484 (30.9) | 3942 (34.3) |
Very high | 113 (9.8) | 1474 (30.0) | 478 (30.5) | 3425 (29.8) |
Number of LDL tests per year, mean (SD) | 0.8 (0.3) | 0.8 (0.2) | 1.0 (0.3) | 0.7 (0.3) |
Number of statinprescriptions per year, mean (SD) | 0.0 (0.0) | 2.6 (0.9) | 2.4 (1.2) | 2.3 (1.2) |